deltatrials
Completed INTERVENTIONAL NCT05935787

Cytoflavin in the Complex Rehabilitation of Stroke Patients

A Multicenter, Double-blind, Placebo-controlled, Randomized Study of the Efficacy and Safety of Sequential Therapy With CYTOFLAVIN® (NTFF POLYSAN, Russia), Solution for Intravenous Infusion and Enteric-coated Tablets, in the Complex Rehabilitation of Patients With Acute Stroke

Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Conditions Stroke
Updated 6 times since 2023 Last updated: Apr 9, 2026 Started: Jun 30, 2023 Primary completion: Jun 26, 2024 Completion: Dec 7, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05935787, this observational or N/A phase trial focuses on Stroke and remains completed. Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshotRecruiting~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshotRecruiting~Sep 2025 – ~Apr 2026 · 7 months · monthly snapshotCompletedApr 16, 2026 – present · 3 months · daily API

Change History

6 versions recorded
  1. Apr 16, 2026 — Present [daily]

    Completed

    Phase: PHASE3None

  2. Sep 2025 — Apr 2026 [monthly]

    Completed PHASE3

    Status: RecruitingCompleted

  3. Jan 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  4. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

Show 1 earlier version
  1. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

It is known that the acute period of stroke occurs is accompanied by oxidative stress, when intense generation of reactive oxygen species (ROS) have a toxic effect, which causes oxidative degradation of proteins, lipids, nucleic acids. Antioxidants may have a positive effect on the processes of reparation, remodeling and neuroplasticity, thus improving the effectiveness of post-stroke rehabilitation. The adjunctive use of drug therapy that improves neuroplasticity may promote accelerated motor learning, which underlies the effects of exercise therapy and physical therapy, speech therapy, and sessions with a psychologist or occupational therapist. CYTOFLAVIN® is a combination of succinic acid, riboflavin, nicotinamide and inosine (riboxin) which has antihypoxic and antioxidant effects. The study hypothetizes that this neurometabolic drug will facilitate learning in stroke survivors and help to acquire new cognitive or motor skills necessary for daily living. The study will be conducted in two parallel groups of stroke survivors: the experimental group will be treated with Cytoflavin along with ohysical rehabilitation, the control group will receive standard rehabilitation course.

Contact Information

Sponsor contact:
  • POLYSAN Scientific & Technological Pharmaceutical Company
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .